Related Experiment Video

Updated: Aug 15, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

[Clinical evaluation of cefozopran in the pediatric field]

H Meguro1, R Fujii, I Terashima

  • 1Department of Pediatrics, Teikyo University Ichihara Hospital.

The Japanese Journal of Antibiotics
|November 1, 1994
PubMed

Insights

Cefozopran (CZOP) is a safe and effective parenteral cephem antibiotic for treating bacterial infections in children. Clinical trials show CZOP eradicated bacteria in pneumonia, cellulitis, and UTI cases with minimal side effects.

Area of Science:

  • Pediatric infectious diseases
  • Pharmacology and therapeutics
  • Antimicrobial agents

Background:

  • Parenteral cephem antibiotics are crucial for treating severe bacterial infections.
  • Cefozopran (CZOP) is a novel parenteral cephem antibiotic.
  • Evaluating the safety and efficacy of new antibiotics in pediatric populations is essential.

Purpose of the Study:

  • To assess the safety and efficacy of cefozopran (CZOP) in pediatric patients with acute bacterial infections.
  • To determine the pharmacokinetic profile of CZOP in children.
  • To evaluate the eradication rates of causative organisms following CZOP treatment.

Main Methods:

  • A clinical study involving 21 children diagnosed with acute bacterial infections.
  • Administration of cefozopran (CZOP) parenterally.
  • Monitoring for adverse events and laboratory abnormalities.
  • Assessment of clinical efficacy, including pathogen eradication.
  • Pharmacokinetic analysis of serum half-life and urinary excretion rates.

Main Results:

  • Cefozopran (CZOP) demonstrated a favorable safety profile, with only one case each of mild side effects and laboratory abnormalities observed.
  • CZOP was highly effective in treating 18 cases of bacterial infections, including pneumonia, cellulitis, and urinary tract infections.
  • Complete eradication of all tested causative organisms was achieved in all treated patients.
  • The serum half-life of CZOP ranged from 1.5 to 1.8 hours.
  • Urinary excretion rates of CZOP were between 63% and 96% within the first 5-8 hours post-administration.

Conclusions:

  • Cefozopran (CZOP) is a safe and effective parenteral antibiotic for pediatric patients with susceptible bacterial infections.
  • The pharmacokinetic properties of CZOP support its use in children.
  • CZOP offers a promising therapeutic option for common pediatric bacterial infections like pneumonia, cellulitis, and UTIs.

More Related Videos

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...